End of Year Update from the pharmaverse Council
2023 Was a Big Year
This was a big year for open-source work in clinical submissions in general. We saw Roche speak about shifting to an open-source backbone for clinical trials. Novo Nordisk spoke publicly of an R based submission to the FDA... [Read more...]